HEADER LIGASE/LIGASE INHIBITOR 21-MAR-13 4JRG TITLE THE 1.9A CRYSTAL STRUCTURE OF HUMANIZED XENOPUS MDM2 WITH RO5313109 - TITLE 2 A PYRROLIDINE MDM2 INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: E3 UBIQUITIN-PROTEIN LIGASE MDM2; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: N-TERMINAL DOMAIN (UNP RESIDUES 21-105); COMPND 5 SYNONYM: DOUBLE MINUTE 2 PROTEIN, XDM2, P53-BINDING PROTEIN MDM2; COMPND 6 EC: 6.3.2.-; COMPND 7 ENGINEERED: YES; COMPND 8 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: XENOPUS LAEVIS; SOURCE 3 ORGANISM_COMMON: CLAWED FROG,COMMON PLATANNA,PLATANNA; SOURCE 4 ORGANISM_TAXID: 8355; SOURCE 5 GENE: MDM2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PUBS 520 KEYWDS PROTEIN-INHIBITOR COMPLEX, PYRROLIDINE, E3 UBIQUITIN LIGASE, P53, KEYWDS 2 NUCLEUS, LIGASE-LIGASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR B.J.GRAVES,C.A.JANSON,C.LUKACS REVDAT 3 28-FEB-24 4JRG 1 REMARK SEQADV REVDAT 2 05-FEB-14 4JRG 1 JRNL REVDAT 1 24-JUL-13 4JRG 0 JRNL AUTH Q.DING,Z.ZHANG,J.J.LIU,N.JIANG,J.ZHANG,T.M.ROSS,X.J.CHU, JRNL AUTH 2 D.BARTKOVITZ,F.PODLASKI,C.JANSON,C.TOVAR,Z.M.FILIPOVIC, JRNL AUTH 3 B.HIGGINS,K.GLENN,K.PACKMAN,L.T.VASSILEV,B.GRAVES JRNL TITL DISCOVERY OF RG7388, A POTENT AND SELECTIVE P53-MDM2 JRNL TITL 2 INHIBITOR IN CLINICAL DEVELOPMENT. JRNL REF J.MED.CHEM. V. 56 5979 2013 JRNL REFN ISSN 0022-2623 JRNL PMID 23808545 JRNL DOI 10.1021/JM400487C REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH C.TOVAR,B.GRAVES,K.PACKMAN,Z.FILIPOVIC,B.HIGGINS,M.XIA, REMARK 1 AUTH 2 C.TARDELL,R.GARRIDO,E.LEE,K.KOLINSKY,K.H.TO,M.LINN, REMARK 1 AUTH 3 F.PODLASKI,P.WOVKULICH,B.VU,L.T.VASSILEV REMARK 1 TITL MDM2 SMALL-MOLECULE ANTAGONIST RG7112 ACTIVATES P53 REMARK 1 TITL 2 SIGNALING AND REGRESSES HUMAN TUMORS IN PRECLINICAL CANCER REMARK 1 TITL 3 MODELS. REMARK 1 REF CANCER RES. 2013 REMARK 1 REFN ESSN 1538-7445 REMARK 1 PMID 23400593 REMARK 1 DOI 10.1158/0008-5472.CAN-12-2807 REMARK 2 REMARK 2 RESOLUTION. 1.90 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX 2005 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.90 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 28.03 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 957499.440 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99.0 REMARK 3 NUMBER OF REFLECTIONS : 16827 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.252 REMARK 3 R VALUE (WORKING SET) : 0.250 REMARK 3 FREE R VALUE : 0.288 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 853 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.010 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.2980 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.2970 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.328 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 853 REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : 0.0110 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 16827 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.90 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.02 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 97.50 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2587 REMARK 3 BIN R VALUE (WORKING SET) : 0.4350 REMARK 3 BIN FREE R VALUE : 0.4550 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.20 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 142 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.038 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1366 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 70 REMARK 3 SOLVENT ATOMS : 128 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 29.40 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 38.00 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 16.13000 REMARK 3 B22 (A**2) : -9.55000 REMARK 3 B33 (A**2) : -6.58000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 4.88000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.30 REMARK 3 ESD FROM SIGMAA (A) : 0.50 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.38 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.51 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.005 REMARK 3 BOND ANGLES (DEGREES) : 1.000 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 22.00 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.680 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.420 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.280 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.340 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.390 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.36 REMARK 3 BSOL : 50.84 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARA REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : ION.PARAM REMARK 3 PARAMETER FILE 4 : RO5313109-A.PRX REMARK 3 PARAMETER FILE 5 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : ION.TOP REMARK 3 TOPOLOGY FILE 4 : RO5313109-A.TPX REMARK 3 TOPOLOGY FILE 5 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4JRG COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 01-APR-13. REMARK 100 THE DEPOSITION ID IS D_1000078410. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 02-JUN-08 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : 31-ID REMARK 200 X-RAY GENERATOR MODEL : RIGAKU MICROMAX-007 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : MIRRORS REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS HTC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : D*TREK REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 16829 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.900 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.2 REMARK 200 DATA REDUNDANCY : 3.300 REMARK 200 R MERGE (I) : 0.08100 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 6.9000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.90 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.97 REMARK 200 COMPLETENESS FOR SHELL (%) : 96.4 REMARK 200 DATA REDUNDANCY IN SHELL : 2.90 REMARK 200 R MERGE FOR SHELL (I) : 0.43600 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.000 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 55.64 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.77 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 50% SATURATED AMMONIUM SULFATE, 0.1M REMARK 280 BIS-TRIS, PH 6.0, 5% PEG 550MME, 5 MM DTT, VAPOR DIFFUSION, REMARK 280 HANGING DROP, TEMPERATURE 278K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 36.77100 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 36.39800 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 36.77100 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 36.39800 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: FULL-LENGTH PROTEIN IS A DIMER, FORMED BY CONTACTS IN THE C- REMARK 300 TERMINAL DOMAIN BUT THE N-TERMINAL DOMAIN ON ITS OWN IS A MONOMER REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH A 348 LIES ON A SPECIAL POSITION. REMARK 375 HOH A 365 LIES ON A SPECIAL POSITION. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 SER A 105 REMARK 465 SER B 105 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 CYS A 73 20.51 -142.23 REMARK 500 LYS B 41 -169.92 -128.50 REMARK 500 CYS B 73 25.30 -142.26 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE I09 A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE I09 B 201 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4IPF RELATED DB: PDB REMARK 900 SAME PROTEIN WITH RG7112, A NUTLIN IN CLINICAL DEVELOPMENT DBREF 4JRG A 21 105 UNP P56273 MDM2_XENLA 21 105 DBREF 4JRG B 21 105 UNP P56273 MDM2_XENLA 21 105 SEQADV 4JRG LEU A 50 UNP P56273 ILE 50 ENGINEERED MUTATION SEQADV 4JRG HIS A 92 UNP P56273 PRO 92 ENGINEERED MUTATION SEQADV 4JRG ILE A 95 UNP P56273 LEU 95 ENGINEERED MUTATION SEQADV 4JRG LEU B 50 UNP P56273 ILE 50 ENGINEERED MUTATION SEQADV 4JRG HIS B 92 UNP P56273 PRO 92 ENGINEERED MUTATION SEQADV 4JRG ILE B 95 UNP P56273 LEU 95 ENGINEERED MUTATION SEQRES 1 A 85 GLU LYS LEU VAL GLN PRO THR PRO LEU LEU LEU SER LEU SEQRES 2 A 85 LEU LYS SER ALA GLY ALA GLN LYS GLU THR PHE THR MET SEQRES 3 A 85 LYS GLU VAL LEU TYR HIS LEU GLY GLN TYR ILE MET ALA SEQRES 4 A 85 LYS GLN LEU TYR ASP GLU LYS GLN GLN HIS ILE VAL HIS SEQRES 5 A 85 CYS SER ASN ASP PRO LEU GLY GLU LEU PHE GLY VAL GLN SEQRES 6 A 85 GLU PHE SER VAL LYS GLU HIS ARG ARG ILE TYR ALA MET SEQRES 7 A 85 ILE SER ARG ASN LEU VAL SER SEQRES 1 B 85 GLU LYS LEU VAL GLN PRO THR PRO LEU LEU LEU SER LEU SEQRES 2 B 85 LEU LYS SER ALA GLY ALA GLN LYS GLU THR PHE THR MET SEQRES 3 B 85 LYS GLU VAL LEU TYR HIS LEU GLY GLN TYR ILE MET ALA SEQRES 4 B 85 LYS GLN LEU TYR ASP GLU LYS GLN GLN HIS ILE VAL HIS SEQRES 5 B 85 CYS SER ASN ASP PRO LEU GLY GLU LEU PHE GLY VAL GLN SEQRES 6 B 85 GLU PHE SER VAL LYS GLU HIS ARG ARG ILE TYR ALA MET SEQRES 7 B 85 ILE SER ARG ASN LEU VAL SER HET I09 A 201 35 HET I09 B 201 35 HETNAM I09 (3R,4R,5S)-3-(3-CHLOROPHENYL)-4-(4-CHLOROPHENYL)-4- HETNAM 2 I09 CYANO-N-[(3S)-3,4-DIHYDROXYBUTYL]-5-(2,2- HETNAM 3 I09 DIMETHYLPROPYL)-D-PROLINAMIDE FORMUL 3 I09 2(C27 H33 CL2 N3 O3) FORMUL 5 HOH *128(H2 O) HELIX 1 1 THR A 27 ALA A 37 1 11 HELIX 2 2 THR A 45 GLN A 61 1 17 HELIX 3 3 ASP A 76 GLY A 83 1 8 HELIX 4 4 GLU A 91 ARG A 101 1 11 HELIX 5 5 THR B 27 ALA B 37 1 11 HELIX 6 6 THR B 45 LYS B 60 1 16 HELIX 7 7 ASP B 76 GLY B 83 1 8 HELIX 8 8 GLU B 91 ARG B 101 1 11 SHEET 1 A 2 GLN A 25 PRO A 26 0 SHEET 2 A 2 LEU A 103 VAL A 104 -1 O VAL A 104 N GLN A 25 SHEET 1 B 2 ILE A 70 HIS A 72 0 SHEET 2 B 2 GLU A 86 SER A 88 -1 O PHE A 87 N VAL A 71 SHEET 1 C 2 ILE B 70 HIS B 72 0 SHEET 2 C 2 GLU B 86 SER B 88 -1 O PHE B 87 N VAL B 71 SITE 1 AC1 12 LEU A 50 ILE A 57 MET A 58 HIS A 69 SITE 2 AC1 12 PHE A 82 VAL A 89 LYS A 90 HIS A 92 SITE 3 AC1 12 ILE A 95 TYR A 96 HOH A 331 HOH A 332 SITE 1 AC2 9 LEU B 50 GLY B 54 MET B 58 HIS B 69 SITE 2 AC2 9 VAL B 89 LYS B 90 HIS B 92 HOH B 325 SITE 3 AC2 9 HOH B 326 CRYST1 73.542 72.796 43.865 90.00 111.78 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013598 0.000000 0.005434 0.00000 SCALE2 0.000000 0.013737 0.000000 0.00000 SCALE3 0.000000 0.000000 0.024550 0.00000